The Role of Combination Therapy in mCRPC
Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.
EP: 1.Incidence and Risk Factors of Prostate Cancer
EP: 2.Presentation and Diagnosis of Prostate Cancer
EP: 3.Screening and Diagnosis of Prostate Cancer
EP: 4.Prostate Cancer Prognosis and Risk Stratification
EP: 5.Differences in the Treatment of Patients with Prostate Cancer
EP: 6.Prostate Cancer: Treatment Decision-Making and the Role of Guidelines
EP: 7.Informing Prostate Cancer Treatment Decisions with Clinical Trials and Real-World Evidence
EP: 8.Systemic Therapy for Prostate Cancer
EP: 9.Androgen Deprivation Therapy for Prostate Cancer
EP: 10.Metastatic Hormone-Sensitive Prostate Cancer Treatment Options
EP: 11.Overview of Castrate-Resistant Prostate Cancer (CRPC)
EP: 12.Treatment Options for Nonmetastatic CRPC
EP: 13.Treatment Approach for Patients With Metastatic CRPC
EP: 14.The Role of Combination Therapy in mCRPC
EP: 15.Improving Clinical Trials in Prostate Cancer
EP: 16.Educating Patients and Caregivers About Prostate Cancer
EP: 17.Advice for Patients With Prostate Cancer
This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.
Dr Rashid K. Sayyid discusses PARP inhibitors like olaparib and rucaparib in combination with other therapies. For example, enzalutamide-olaparib was approved based on TRITON3 for certain mutations, while olaparib-abiraterone was approved first-line for BRCA-mutated cancer per PROPEL. He explains PARP inhibitors may radiosensitize, improving radium Ra 223 dichloride efficacy.
The ongoing COMRADE phase 1/2 trial established olaparib-radium dosing in phase 1 and showed 6-month 57% radiographic progression-free survival and 56% 1-year overall survival. Phase 2 is now examining olaparib-radium efficacy for radiographic progression-free survival with 213 patients. Upcoming results over next few years.
In summary, Dr. Sayyid overviews emerging prostate cancer approaches, including PARP inhibitor combinations with antiandrogens like enzalutamide or abiraterone for certain mutations, as well as combinations with radium Ra 223 dichloride now under phase 2 investigation.
*Video synopsis is AI-generated and reviewed by CURE editorial staff.
Dickey Betts Died, ‘Shopaholic’ Author Announces Cancer Diagnosis and More
April 19th 2024From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.
Read More
